Quality of life in patients with K-RAS wild-type colorectal cancer: The CO.20 phase 3 randomized trial

Cancer

Volumn 120, Issue 2, 2014, Pages 181-189

  Ringash, Jolie ^a   Au, Heather Jane ^b   Siu, Lillian L ^c   Shapiro, Jeremy D ^d   Jonker, Derek J ^e   Zalcberg, John R ^f   Moore, Malcolm J ^c   Strickland, Andrew ^d   Kotb, Rami ^h   Jeffery, Mark ⁱ   Alcindor, Thierry ^j   Ng, Siobhan ^k   Salim, Muhammad ^l   Sabesan, Sabe ^m   Easaw, Jay C ⁿ   Shannon, Jenny ^o   El Tahche, Fabyolla ^p   Walters, Ian ^q   Tu, Dongsheng ^g   O'Callaghan, Christopher J ^g  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g QUEEN S UNIVERSITY   (Canada)

^h UNIVERSITÉ DE SHERBROOKE   (Canada)

ⁱ CHRISTCHURCH HOSPITAL   (New Zealand)

^j MONTREAL GENERAL HOSPITAL   (Canada)

^k ST JOHN OF GOD HOSPITAL   (Australia)

^l Allan Blair Cancer Centre   (Canada)

^m TOWNSVILLE HOSPITAL   (Australia)

ⁿ TOM BAKER CANCER CENTRE   (Canada)

^o NEPEAN HOSPITAL   (Australia)

^p UNIVERSITY OF SYDNEY   (Australia)

^q BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

colorectal cancer; K RAS; palliative chemotherapy; patient reported outcomes; quality of life; questionnaires

Indexed keywords

BRIVANIB ALANINATE; CETUXIMAB; K RAS PROTEIN; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FUNCTIONAL ASSESSMENT; GENERAL CONDITION DETERIORATION; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; SELF REPORT; TREATMENT OUTCOME;

EID: 84891851298     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28410     Document Type: Article

References (17)

1. Au HJ, Karapetis CS, O'Callaghan CJ, et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol. 2009; 27: 1822-1828.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
3. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 2040-2048.
4. Garrett CR, Siu LL, El-Khoueiry A, et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011; 105: 44-52.
5. Ayers M, Awad M, Malone D, et al. Correlation between k-ras status and efficacy results from a phase I/II study of brivanib alaninate in combination with cetuximab in patients (pts) with advanced or metastatic colorectal cancer (CRC). Presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 15-17, 2009; San Francisco, CA.
6. Siu LL, Shapiro JD, Jonker DJ, et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol. 2013; 31: 2477-2484.
7. Tu D,. Minimization procedure. In:, Chow S-C, ed. Encyclopedia of Biopharmaceutical Statistics. New York: Marcel Dekker; 2003: 614-618.
8. Luckett T, King MT, Butow PN, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol. 2011; 22: 2179-2190.
9. McDowell I, Newell C,. Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed. New York: Oxford University Press; 1996.
10. Uwer L, Rotonda C, Guillemin F, et al. Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer. Health Qual Life Outcomes. 2011; 9: 70.
11. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-376.
12. Fayers P, Aaonson N, Bjordal K, Curran D, Groenvold M, on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels, Belgium: EORTC Quality of Life Study Group; 1999.
13. Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer. 2011; 19: 1753-1760.
14. Osoba D, Rodrigues G, Myles J, Zee B, Pater J,. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998; 16: 139-144.
15. Hochberg Y,. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1998; 75: 800-802.
16. Osoba D, Zee B,. Completion rates in health-related quality-of-life assessment: approach of the National Cancer Institute of Canada Clinical Trials Group. Stat Med. 1998; 17: 603-612.
17. Basch E,. Toward patient-centered drug development in oncology. N Engl J Med. 2013; 369: 397-400.